Lara Mangravite, PhD — President of Sage Bionetworks
Lara Mangravite, PhD is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.
Diane Gary — Director, Business Operations
Diane Gary has responsibility for the organization’s finance, human resources, grant management and general business activities. Ms. Gary has held similar roles in other early-stage companies, including Rosetta Inpharmatics through the initial funding, IPO and acquisition by Merck & Co. Inc., and KidStar Interactive Media. Most recently, she was HR Director for Merck’s Seattle and San Francisco research sites. Prior experience also includes work with a hospital foundation, with a nonprofit healthcare association, and on the board of the Country Doctor Community Health Centers. Ms. Gary holds an MBA degree from the University of Washington.
Justin Guinney, PhD — Director, Computational Oncology
Justin Guinney is the Director of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. Justin is an expert at large-scale analysis of genomic data, and works regularly with clinicians to link these models to complex cancer phenotypes. Prior to joining Sage Bionetworks, Justin co-founded and managed a software company called FiveSight Technologies, now part of Intalio Corp. Dr Guinney received a BA from the University of Pennsylvania in History, a BS from the University of Illinois, Urbana-Champaign in Electrical Engineering, and a PhD from Duke University in Computational Biology and Bioinformatics.
Mike Kellen, PhD — Director, Technology and Software Development
Michael Kellen leads the technology platforms and services team at Sage Bionetworks. Since 2009, the team has supported open projects and challenges in the collaborative analysis of human health data through the development of the Synapse platform, and by providing support with data hosting, curation, and analysis. The team is now expanding scope into the collection of rich human phenotypic data though the development of the Bridge platform. Michael has over 10 years experience developing software for academic and corporate users in the life sciences, and has brought several award-winning products to market in this space covering simulation, data capture and analysis workflow, data integration, and team collaboration. Prior to Sage, Michael held a variety of positions with Teranode corporation since joining as the company’s first employee in 2002, covering product development, field consulting, product management, and development management. Michael completed a doctorate in bioengineering at the University of Washington in 2002 with a focus in computational biology where he also helped develop scientific modeling and simulation technology subsequently licensed by Teranode.
Thea Norman, PhD — Director, Strategic Development
Dr. Norman is the Director of Strategic Development at Sage Bionetworks. She works closely in partnership with Dr. Gustavo Stolovitzky of IBM to oversee the running of the Sage-DREAM Challenges. DREAM Challenges foster a collaborative framework for researchers to rapidly evolve predictive disease models for tough problems in biology and medicine that would otherwise take years to produce. Dr. Norman also oversees the design and development of Sage Bionetworks BRIDGE platform. Prior to joining Sage Bionetworks, Dr. Norman spent 12 years as a science, alliance and business leader at two start-up biotechnology companies (Ironwood and Ambrx). Dr. Norman is a co-inventor on seven issued patents including that for the composition of Linzess (which Dr. Norman developed), a First in Class treatment for Irritable Bowel Syndrome. Dr. Norman holds a PhD in Chemistry from the University of California, Berkeley.
John Wilbanks — Chief Commons Officer
John Wilbanks is the Chief Commons Officer at Sage Bionetworks. Previously, Wilbanks worked as a legislative aide to Congressman Fortney “Pete” Stark, served as the first assistant director at Harvard’s Berkman Center for Internet & Society, founded and led to acquisition the bioinformatics company Incellico, Inc., and was executive director of the Science Commons project at Creative Commons. In February 2013, in response to a We the People petition that was spearheaded by Wilbanks and signed by 65,000 people, the U.S. government announced a plan to open up taxpayer-funded research data and make it available for free. Wilbanks holds a B.A. in philosophy from Tulane University and also studied modern letters at the Sorbonne.